NCT02430714View on ClinicalTrials.gov

Post-marketing Surveillance of Lenvatinib Mesylate (Lenvima Capsule) in Patients With Unresectable Thyroid Cancer (Study LEN01T)

CompletedOBSERVATIONAL
Enrollment

629

Participants

Timeline

Start Date

May 20, 2015

Primary Completion Date

November 6, 2016

Study Completion Date

November 6, 2016

Conditions
Thyroid Neoplasms
Interventions
DRUG

Lenvatinib

24mg once daily oral dosing to Unresectable thyroid cancer patients

Trial Locations (2)

Unknown

Osaka

Tokyo

All Listed Sponsors
lead

Eisai Co., Ltd.

INDUSTRY

NCT02430714 - Post-marketing Surveillance of Lenvatinib Mesylate (Lenvima Capsule) in Patients With Unresectable Thyroid Cancer (Study LEN01T) | Biotech Hunter | Biotech Hunter